Evidence map›Paper›PMID 33133147›Full record

ArticleFrontiers in genetics2020

Novel Splicing Variant in the

Katerina Slaba, Hana Noskova, Petra Vesela, Jana Tuckova, Hana Jicinska, Tomas Honzik, Hana Hansikova, Petra Kleiblova, Petr Stourac, Petr Jabandziev and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Katerina SlabaDepartment of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
Hana NoskovaCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Petra VeselaCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Jana TuckovaDepartment of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
Hana JicinskaDepartment of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
Tomas HonzikDepartment of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
Hana HansikovaDepartment of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
Petra KleiblovaInstitute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
Petr StouracDepartment of Pediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
Petr JabandzievDepartment of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
Ondrej SlabyCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Dagmar ProchazkovaDepartment of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
University Hospital Brno · CZCentral European Institute of Technology – Masaryk University · CZGeneral University Hospital in Prague · CZMasaryk University · CZCharles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases with the phosphomannomutase 2 (PMM2)-CDG being the most common form of CDG. Most of these monogenic diseases are autosomal recessive and have multi-systemic manifestations, mainly psychomotor retardation, facial dysmorphisms, characteristic distribution of the fat pads, and variable coagulation abnormalities. The association of fetal hydrops with CDG has been reported, and pericardial effusion was also rarely observed in patients with PMM2-CDG. Here we describe an infant boy with PMM2-CDG. The diagnosis was suspected based on inverted nipples, fat pads, and combined coagulopathy. However, the primary symptom was progressive pericardial effusion leading to patient death at the age of 3 months. Screening for CDG performed by the use of isoelectric focusing of serum transferrin showed a typical PMM2-CDG pattern. Exome sequencing revealed one common pathogenic variant (c.691G > A/p.Val231Met) and one novel variant (c.447 + 3dupA) in the

Indexed as

novel splicing variantpericardial effusionphosphomannomutase 2PMM2-CDGwhole exome sequencing

Identifiers

PMID33133147
PMCPMC7575812
OpenAlexW3092386107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.